PHOENIX, May 10, 2018 (GLOBE NEWSWIRE) -- Richard T. Schumacher, President and CEO of Pressure Biosciences, Inc. (OTCQB:PBIO)
(“PBI” and “the company”), joined Everett Jolly on the “Stock Day” podcast with exciting news about the first contract to be
received that is based on their recent acquisition of intellectual property from BaroFold Inc.
On December 12, 2017, PBI purchased all of BaroFold Inc.’s assets, including Intellectual Property (IP). Representatives of
BaroFold previously stated that the company spent more than $20 million in investment dollars into obtaining and expanding their IP
estate.
“In our wildest dreams, we didn’t think we’d be securing such an important contract so soon after the acquisition. This is the
first contract that is based primarily on utilizing the patented PreEMT platform acquired just a few months ago from BaroFold. We
view this as both significant and exciting, and believe that additional contracts will soon be secured,” said Schumacher. In
addition to this contract from an international biopharma company, two other protein-based bio-therapeutic companies have
approached PBI over the past several weeks asking about potential collaborations with studies based on the recently acquired
intellectual property.
Schumacher goes on to explain the intricacies of the company’s pressure-based products and services. Hundreds of labs around the
globe utilize PBI’s pressure-based systems (pressure cycling technology, or PCT) to extract proteins from all types of cells,
whether it be plant, animal, microbial, or human, and whether the cells are normal or cancerous. This process works similarly to a
sponge, squeezing the cells until they break. Schumacher gives an analogy that their pressure system works like a sponge – it
“gently and controllably” squeezes the proteins out of the cells, as compared to competitive methods that use mechanical means to
beat up cells, strong acids to break cells, or other harsh methods. Schumacher believes that because PCT is so controllable
(pressure can be instantly turned on and off, analogous to turning light on and off with a light switch), that the PCT platform
offers researchers a method to generate higher quality proteins, as compared to other current methods), which is a critical
advantage to the researcher.
The success of the PCT technology has been apparent in the company’s financial reports as well. The last 8 quarters have shown
continuous sales growth over the same quarter of the previous year. As the pharmaceutical industry switches from chemical-based to
biological and protein-based products, opportunities for PBI to expand their reach and continue to increase revenue will surely
come to reality.
When asked about the company’s outlook and plans for 2018, Schumacher replied “We are very excited about the potential of 2018 –
we see this year shaping up well.” The company recently established a solid sales team in the field (they achieved $2.24M in
revenue in 2017 with mostly just one sales person in the field) and added additional key opinion leaders in proteins who have
published and presented information about the advantages and benefits of PBI’s technology over the past year. In addition, the
company has developed three new instruments that will be released within the year. These updates set the stage to continue the
company’s trend of 4 consecutive years with increased revenue. “We expect to make it 5 years in a row… We’re very optimistic about
2018.”
“Stock Day” host and capital markets veteran Everett Jolly believes the stock is tremendously undervalued at its current price
of $3.70 per share.
Richard T. Schumacher also spoke about the scientific aspects and importance of protein extraction, and talked about some new
opportunities that he saw on the horizon. To hear this information and more, please click the following link to the full
interview.
https://upticknewswire.com/featured-interview-ceo-ric-schumacher-of-pressure-biosciences-inc-otcqb-pbio-5/
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based
solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static)
and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform
that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control
bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based
products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control,
soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in
the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from
BaroFold, Inc. to allow immediate entry into the biologics contract research services sector, and (2) the use of our
recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable
nano-emulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended
shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal
technologies.
Safe Harbor Statement
Statements contained in this press release regarding PBIO's
intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts,
and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ
materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are
not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K
for the year ended December 31, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes
no obligation to update any of the information included in this release, except as otherwise required by law.
About Uptick Newswire and the “Stock Day” Podcast
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and
bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network
“Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video
Interview Studio located in Phoenix, Arizona.
Investors Hangout is a proud sponsor of Uptick Newswire’s “Stock Day” Podcast.
http://www.investorshangout.com
For more information about PBIO and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Investor Contacts:
Pressure BioSciences,
Inc.
Richard T. Schumacher
President & CEO
Nathan P. Lawrence, Ph.D.
VP of Marketing and Sales
(508) 230-1828 (T)
